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ABSTRACT
Ever since its initial discovery in Drosophila, hedgehog signaling has been 
linked to foregut development, The mammalian genome expresses three Hedgehog 
paralogues, sonic hedgehog (Shh), Indian Hedgehog, and desert hedgehog. In 
the mucosa of the embryonic and adult foregut, Shh expression is the highest. It 
has now become clear that hedgehog signaling is of pivotal importance in gastric 
homeostasis. Aberrant activation of hedgehog signaling is associated with a range of 
pathological consequences including various cancers. Also in gastric cancer, clinical 
and preclinical data support a role of Hedgehog signaling in neoplastic transformation, 
and gastrointestinal cancer development, also through cancer stroma interaction. 
Technological advance are facilitating monitoring Hedgehog signaling broadening 
options for the more efficient screening of individuals predisposed to eventually 
developing gastric cancer and targeting Hedgehog signaling may provide opportunities 
for prophylactic therapy once atrophic gastritis develops. Nevertheless, convincing 
evidence that Hedgehog antagonists are of clinically useful in the context of gastric 
cancer is still conspicuously lacking. Here we analyze review the role of Hedgehog 
in gastric physiology and the potential usefulness of targeting Hedgehog signaling 
in gastric cancer.
INTRODUCTION
Hedgehog proteins are fundamental regulators 
of embryological development, and tissue homeostasis 
in adult organisms. Disturbed hedgehog signaling is 
associated, amongst others, with a range of congenital 
disabilities, oncological malignancies and immunological 
defects [1]. Hedgehog proteins intercellular signaling 
molecules of unusual and fundamental relevance as 
also illustrated by their substantial conservation across 
the animal kingdom [2-5]. Initially recognized as a 
segment polarity gene in Drosophila, now numerous 
vertebrate paralogues have been found, and in mammals, 
these include Sonic Hedgehog (Shh), Desert Hedgehog 
(Dhh), and Indian Hedgehog (Ihh), with Shh being 
the most comprehensively characterized [5]. Although 
mainly associated with organogenesis and general and 
embryological formation of the intestines, in particular, 
Hedgehog signaling remains active until death and serves 
to maintain lifelong histostasis in the intestinal tract and 
also the immune system [6-8]. The pathophysiological 
importance of Hedgehog signaling is illustrated by 
the observation that continuous hedgehog signaling is 
an essential permissive factor in endodermal cancer 
development [9-11]. With regard to the above, especially 
the stomach is relevant, where the morphogennot only 
maintains pit-gland asymmetry, but also fosters the 
development of gastric cancer, homeostasis, and neoplastic 
transformation [12-14]. Part of this nefarious functionality 
is related to the initiation of gastric inflammation due to 
Helicobacter infection [12]. As stated, although classically 
associated with gestation, the role of Hedgehog pathway 
also has important functionality beyond embryogenesis 
and a potentially vicious one concerning oncological 
disease. In cancer, both autocrine Hedgehog signaling 
and paracrine signaling (through the tumor stroma 
that would thus nurture the tumor cells) of Hedgehog 
ligands is well-established [15, 16]. Both autocrine and 
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paracrine Hedgehog signaling should be sensitive to 
pharmacological inhibitors and are thus tested in clinical 
trials in addition to an intense preclinical research 
effort[16]. The importance of Hedgehog signaling gastric 
pathophysiology has led to hopes that pharmacological 
inhibitors of this signaling may become useful for 
combating oncological disease in the stomach and this 
consideration prompted us to review here the detailed 
molecular mechanism by which Hedgehog influences 
gastric pathophysiology and to evaluate the evidence 
that anti-Hedgehog strategies will prove effective in this 
respect.
The physiological importance of Hedgehog signaling 
in the physiology of the proximal tract is illustrated by 
the phenotypes observed in mice with genetic loss of 
Hedgehog paralogues. Genetic knockout of both Shh 
and Dhh provoke by malrotation of the gastrointestinal 
tract, oesophageal atresia, gastric overgrowth and other 
gross abnormalities [17, 18]. The specific importance of 
Hedgehog signalling for the stomach in this respect is 
illustrated by the observation in mice from embryonic 
day 16 onwards as dichotomy occurs in that the foregut 
and at the level of antrum and pyloric border region 
which becomes dramatically more active with respect to 
Hedgehog signalling as compared to the adjacent duodenal 
tissues [19], and also is proposed to maintain pit-gland 
asymmetry in the stomach[7, 20]. Thus the relevance of 
Hedgehog signaling for gastric physiology seems evident. 
With regard to pathophysiology, Hedgehog signaling is 
suggested to be pivotal for gastric cancer progression in 
both of humans and animals, but a definite etiological role 
has not yet been shown for this pathway in gastric cancer. 
To further analyze the precise evidence available in this 
respect it is essential first to review the molecular details 
of the molecular signaling involved [21]. 
Hedgehog signaling: An overview 
Hedgehog signaling in general is unusual and 
complicated, and an immense scientific effort has been 
necessary to unravel its general principles [16, 22-24]. 
Signaling is initiated by the different Hedgehog ligands, in 
casu Shh, Ihh, and Dhh. In the classical Hedgehog signal 
pathway activation, these different ligands bind a common 
cognate membrane-bound receptor called Patched that has 
approximately 1,500 amino acids. The protein transverses 
the plasma membrane twelve times and thus strongly 
resembles ABC transporter proteins. In accordance both 
The N-terminal and C-terminal domains of the protein 
reside at the cytoplasmic side of membrane, The tertiary 
conformational of Patched allows Hedgehog ligands to 
bind via the interaction with two extracellular loops [16, 
25]. There are two genes encoding Patched receptors in 
humans;  which are dominated as PTCH1 and PTCH2, and 
differ slightly concerning their amino acid configuration 
in the N-terminal region [16, 25]. While both PTCH1 and 
PTCH2 receptors are associated with numerous human 
cancers, concerning gastric cancer, especially PTCH1 is 
the relevant gene product. The function of Patched is to 
exclude the second receptor, called Smoothed from the 
primary cilium and retained Smoothened in a vascular 
compartment/ Binding of Hedgehog to PTCH release this 
inhibition enabling further downstream signaling [16, 26]. 
Figure 1 provides a graphical representation. 
Following binding of Hedgehog to Patched. 
Smo translocates to the primary cilium in the cell 
membrane. The subsequent signaling culminates in 
altered transcription through Gli transcription factors. 
The molecular details of Smoothened signaling to Gli 
is still partly obscure but involves the microtubule 
transport proteins [16, 27]. The Gli family are members 
of the Kruppel family of zinc finger transcription factors 
and a role for three different Gli proteins in Hedgehog 
signalling has been identified, Gli1, Gli2, and Gli3, each 
with a distinctive role [16], In the absence of Smoothened 
activation, GLI1 and GLI2 are transcriptional repressors, 
but following activation of the pathway these proteins 
are converted to transcriptional activators [16, 28]. The 
role Gli3 appears to be mainly as a negative regulator of 
Hedgehog signaling. It is thus possible to interfere with 
Hedgehog signaling at different levels, although clinically 
the use of Smoothened inhibitors has gained the most 
attention.
Role of Hedgehog Signalling in Gastric Homeostasis
Ever since its initial detection in Drosophila, 
Hedgehog has long been associated with foregut 
development. Of the three mammalian Hedgehogs (3) 
Shh levels are most highly expressed h, in the mucosa of 
the embryonic foregut, [29]. Also in other foregut-derived 
organs such as the lung, Shh expression is prominent, 
reflecting the embryonal situation [30-33]. Table 1 
lists expression patterns in physiology and pathology. 
Interestingly high Shh expression in the stomach is lost 
upon the development of intestinal metaplasia (Table.1), 
suggesting that gastric epithelium-specific effects of the 
morphogen [12]. Indeed Shh controls gastric epithelial cell 
maturation and differentiation in the adult stomach[7, 34]. 
During progression from the inflamed stomach to 
gastric cancer, the epithelium goes through defined series 
of morphological transitions. First, the acid-producing 
parietal cells are lost and are replaced by mucus-secreting 
cells that express spasmolytic polypeptide (SP) or trefoil 
factor 2.7 [35]. Mostly in mice, but also in human 
subjects, the presence of SP-expressing mucosa (SPEM) 
defines gland atrophy [36, 37]. Together with atrophy of 
the parietal cells [33] Shh expression diminishes [38, 39] 
Although Shh expression diminishes along with the loss of 
parietal cells [15] the expanding mucous cell compartment 
or SPEM continues to produce Shh in both human subjects 
[34, 38] and rodents,[39, 40] but appears to remain as the 
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unprocessed pre-morphogen. Thus functionally expression 
is lost.  Studies suggest that aberrant Hh signaling in 
cancer functions mainly as either autocrine or paracrine 
regulator. Especially in stem cell niche Processing of Shh 
to its active form (19 kilodaltons) in parietal cells becomes 
compromised in the absence of gastric acid [41, 42] 
Atrophy of parietal and zymogenic (chief cell) lineages 
result in hypochlorhydria and reduced serum pepsinogen 
I (A) levels compared to pepsinogen II (C)[43-49]. These 
zymogens are proteins encoded by different gene loci that 
are used clinically to identify pre-neoplastic changes in 
the stomach [49]. Pepsinogens A and C are converted to 
the enzymatically active aspartic proteinases, pepsin A and 
pepsin C, through intramolecular self-cleavage [49, 50]. 
Pepsinogen A is produced primarily in the mouse corpus 
by parietal cells, whereas pepsinogen C is mainly produced 
by both mucous neck and chief cells throughout the 
stomach h[41]. This result is consistent with the exclusive 
expression of pepsinogen A in the human corpus and not 
the antrum, whereas pepsinogen C marks mucous cells 
of both the antrum and corpus (www.proteinatlas.org). 
Pepsin A prefers to cleave proteins at hydrophobic and 
aromatic residues, particularly at phenylalanine (F) when 
the pH is less than 2. By contrast, pepsin C recognizes 
a broader consensus site and uses more comprehensive 
pH spectrum than pepsin A[50, 51]. Explicitly, it’s shown 
using site-directed mutagenesis that pepsin A cleaves the 
nascent 45-kilodalton Shh polypeptide at residue 200 
(SGGCF200|P) to generate the active 19-kilodalton form, 
whereas pepsin C does not cleave SHH peptide[41]. This 
may account for the absence of Shh expression in atrophic 
gastritis.
Regulation of Gastrin and Gastric Acidity by Shh
Several studies have examined the impact of 
blocking Hedgehog signaling in vivo, for instance by 
employing a transgenic mouse that secretes a natural 
-inhibitor of Hedgehogs called HHIP employing 
the parietal cell-specific H+, K+-ATPase β subunit 
promotor [52]. This approach showed that loss of 
Hedgehog signaling in parietal cells reduces H+, K+-
ATPase gene expression and gastric acid secretion 
[52]. Usually, hypochlorhydria stimulates gastrin gene 
expression through a decrease in Somatostatin levels 
[53] Accordingly, increased plasma gastrin occurred in 
the HHIP transgenic mice, concomitant with reduced 
somatostatin expression. Both antral G and D cells possess 
primary cilia, organelles protruding from the plasma 
membrane, essential for transducing Hedgehog signaling 
[54, 55]. Therefore, gastric endocrine cells may well be 
capable of responding directly to Shh. Functionally, this 
idea is supported by the observation that that transgenic 
overexpression of GLI2 suppresses gastrin gene 
expression [56]. Taken together, the production of Shh 
by parietal cells and the ability of gastric endocrine cells 
to sense the ligand through primary cilia are consistent 
with a central role for Hedgehog signaling in the feedback 
regulation of gastric acidity.
Table 1: Small molecules related Hedgehog expression in Gastric Cancer
S/No Homologs Normal Intestine
Stomach 
Metaplasia
Tumor Techniques ReferenceIntestinal Diffuse
1 Shh Gland Epithelium Undetectable elevated Undetectable 
IHC,RT-PCR
IHC, RT-PCR
RT-PCR,IHC,IMF
[62]
[63]
[64]
[65]
2 Ihh Pit Epithelium Undetectable elevated Undetectable
IHC, RT-PCR
PCR,IHC,IMF
[62]
[66]
3 Dhh Gland Epithelium Undetectable elevated elevated
IHC, RT-PCR
PCR,IHC,IMF
[62]
[66]
4 Ptch1 Pit Mesenchyme Detected elevated elevated
IHC, RT-PCR
RT-PCR, IMF
RT-PCR, LacZR
[62]
[66]
[65]
5 SMO Pit / Gland Mesenchyme Detected elevated elevated
IHC, RT-PCR
PCR,IHC,IMF
[62]
[66]
6 Gli 1 Pit / Gland Mesenchyme Undetectable elevated elevated
IHC, RT-PCR
PCR,IHC,IMF
[62]
[66]
7 Gli 2 Pit Mesenchyme Undetectable elevated elevated
IHC, RT-PCR
PCR,IMF
[62]
[66]
8 Hip Detected Not Reported Undetectable Not Reported RT-PCR, IMF [62, 66]
9 BOC Pit Undetectable elevated elevated IHC, RT-PCR [62]
NOTE: NA: not available; Hh: Hedgehog; Gli: glioma-associated oncogene; Ptch: Patched; Smo: Smoothened; Shh: Sonic 
Hh; IHC = immunohistochemistry, ISH= in situ hybridization, LacZ reporter. RT-PCR real-time PCR.
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Modes of hedgehog signaling in gastric cancer
Upregulation of Hedgehog signaling pathway is 
involved in tumor development [57]. De Sauvage and 
Rubin postulated models for Hedgehog signaling in 
human cancer development t[57]. The type I cancers are 
ligand-independent and involve constitutive stimulation 
of downstream signaling molecules (e,g, loss of Patched), 
and an example is basal cell carcinoma. Type II are cancers 
ligand-dependent were both the autocrine, or juxtacrine 
signaling mechanisms are involved as seen in pancreatic 
tumors. In type III cancers also ligand-dependency is 
observed but this type displays paracrine type signaling 
[57]. Table 1 provides information on these type of tumors 
in the context of stomach cancer. Remarkably, these 
models ignore the involvement of non-canonical signaling 
mechanisms. A number of studies have evaluated the role 
of cyclin B1 interaction with Patched, in which a Ptch1-
cyclin B1 complex is formed at the plasma membrane in 
a cyclin kinase-1 (Cdk1)-dependent fashion [58, 59]. This 
results in a reduction in the mitotic index by the separation 
of cyclin B1/Cdk1 complex from the nuclear machinery 
resulting in decreased proliferation. Shh binding to 
patched release the complex and thus fosters cell cycle 
progression through G2/M phase checkpoint. Obviously, 
Smoothened inhibitors do not affect this process. Another 
study documents Hedgehog-independent activation of 
Patched through the action of proteases and in particular 
Caspase 3, splitting the C-terminal from Patched [57, 
60, 61]. It is likely that such non-canonical signaling 
contributes to the pro-oncogenic effects of Hedgehog. 
Cross-Links between Hedgehog Signaling, 
Chronic Inflammation, and Gastric Cancer
As stated, Hedgehog signaling in the stomach plays 
a significant role in gastric development, homeostasis, 
and neoplastic transformation [67]. Initially, Shh was 
somewhat ignored in the context of gastric cancer, despite 
the evidence that Shh is highly expressed in gastric cancer 
cell lines [66]. Although increased levels of Shh have 
been reported in gastric cancers, its specific role in gastric 
transformation remains elusive but carries significance 
because of the availability of Hh antagonists. A link exists 
through the immune system; several studies show that 
Figure 1: A simplified model of the mammalian Hh pathway. In the ‘OFF’ state, Patch inhibits the activity of SMO. Inactive 
SMO is unable to inhibit Sufu, which promotes processing of the Gli transcription factors in favour of shorter, transcriptional repressor 
forms (GliR). In the ‘ON’ state, Hh ligands bind to and inhibit Patch, thus releasing SMO activity and in turn blocking Sufu. Gli processing 
is then shut down, leading to the accumulation of transcriptional activator forms (GlIA).
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in gastritis the phenotype of infiltrating myeloid cells 
changes over time to become myeloid-derived suppressor 
cells (MDSCs) and that this phenotypic switch requires 
Hedgehog signaling. More specifically, expression 
of GLI1, which targets Slfn4 (mice) and SLFN12L 
and SLFN5 (humans), is an early marker for chronic 
inflammation-associated myeloid cells in their transition 
towards the MDSC phenotype. As MDSCs are essential 
for immune-evasion for transformed cells, Hedgehog 
signaling can thus favor neoplastic development. 
Hedgehog Signaling pathway inhibitors 
The Hedgehog signaling pathway is a significant 
target for cancer therapy. Various molecules that 
may inhibit the pathway have been evaluated in both 
preclinical and clinical studies. These inhibitors include: 
SMO inhibitors, ligand-receptor inhibitors, Gli targeted 
inhibitors, and these classes of molecules are Illustrated 
in figure 2.
SMO Inhibitors
Cyclopamine, originally isolated from the flower 
veratrum californicum that causes congenital disabilities 
when eaten by pregnant cattle, was the first compound 
that was used as a Hedgehog inhibitor and it targets 
SMO. Consequently, GLIs activation is inhibited. In 
the clinic, it is side effect-prone and exhibits substantial 
toxicity [68]. Frustratingly, mice studies involving 
rhabdomyosarcoma and osteosarcoma models, reveal no 
significant impact on cancer cells metastasis or growth 
[69, 70]. From mouse model studies, skin ulcerations 
and scrubby coat were reported as particularly noticeable 
skin toxicity; halted even studies initiated to ascertain 
cyclopamine therapeutic dosing [70]. Adverse effects 
of cyclopamine in conjunction with other limitations 
such as acid sensitivity and poor solubility have now 
halted its clinical development as a potential compound 
for the treatment of cancer and prompted efforts aimed 
at. Identifying molecules potentially more suited. This 
led to the development of the acid stable and water-
soluble compound vismodegib (GDC-0449), which was 
eventually approved by the FDA for the treatment of 
advanced (Locally), recurrent and metastatic skin cancer. 
Another semisynthetic novel analogue of cyclopamine 
(Saridegib (IPI-926) was developed with enhanced 
potency and metabolically stable[71]. Other inhibitors that 
impede SMO include LEQ506, PF-0449913, LDE-225 
(erismodegib), and BMS-833923. It is important to note 
that such compounds will not impair Patched-dependent 
Smoothened-independent non-canonical signaling.
Figure 2: Molecular sites targeted by Hh signaling pathway inhibitors. These inhibitors target different components of Hh 
signaling, including Shh, SMO, and GLI1. These encompass natural compounds, their chemical derivatives, a monoclonal antibody, and 
chemicals identified from screening libraries.
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GLI inhibitors
Also in view of resistance development against 
vismodegib through SMO mutation efforts have been 
made to target Gli. Two inhibitory compounds (GANT 
58.  And GANT 56) were identified through cellular 
screens aimed at identifying compounds able to inhibit 
transcription mediated by GLI. Both compounds at 
the cellular level have been revealed. Understanding 
the mechanism of action of these compounds at a 
molecular level is still incomplete. GLI1 posttranslational 
modification by GANT 61 impedes binding to DNA or 
changes the conformational structure of the GLI1-DNA 
complex. In xenograft mice, models of human prostate 
cancer cells inhibition of cancer cell growth is observed 
[72]. A study by Hyman et al. also succeeded in identifying 
four further Hedgehog inhibitors apparently acting 
downstream of Smoothened: HPI-1, HP-2, and HP-3 are 
thought to inhibit signaling by targeting a posttranslational 
modification of GLI or interaction between GLI and a co-
factor. HPI-4 was considered to be the only agent that acts 
by perturbing ciliogenesis, although the mechanism by 
which HPI-4 disrupts ciliogenesis was not clarified [73]. 
Again, it is important to note that such compounds will 
not impair Patched-dependent Smoothened-independent 
non-canonical signaling.
ligand-receptor interactions disrupting Agents
A monoclonal antibody 5E1 (ch5E1) from murine-
human chimeric has been proven to bind Shh and thereby 
to inhibit Hedgehog signaling[74]. A small molecule 
(Robotnikinin) was also identified as a Hedgehog 
signaling inhibitor in a microarray-based screening effort. 
Robotnikinin binds to Shh thereby inhibiting the activation 
of Hedgehog signaling [75]. Other new ligand processing 
blocking agents have been identified in high-throughput 
screens and appear to have different mechanisms of 
actions, including interfering with Shh palmitoylation by 
targeting Hh acyltransferase [76, 77]. These molecules 
have obvious potential as they also target non-canonical 
Hedgehog signaling.
Gastric cancer Treatment using Hh pathway 
targeted agents
For gastric cancer treatment using Hh signaling 
targeted agents, only two clinical trials have been 
performed. A phase II multi-centered, randomized, a 
prospective clinical trial involving 124 participants 
was performed to determine the vismodegib efficacy, 
potency, and safety. For adenocarcinoma patients under 
FOLFOX chemotherapy, vismodegib an SMO inhibitor 
was administered in conjunction with this regimen. 
The study did not meet the primary endpoint with a no 
significantly-improved progression-free survival between 
the placebo group and vismodegib group (9.3 months vs. 
11.5; p = 0.34), although with a noticeable tendency for 
prolonged progression-free survival [78]. The lack of 
a statistically significant result may well stem from this 
study being underpowered. Lack of good biomarkers 
that can act as surrogates for progression-free survival 
can also be considered a confounding factor. CD44 
immunopositivity has been established as a biomarker of 
gastric cancer stem cells. CD44 expression was analyzed 
in phase II clinical trial samples of gastric tumors and were 
associated with improved survival. Patients who received 
chemotherapy alone had poor survival together with high 
CD44 suggesting a potential role for CD44 as a biomarker 
in the treatment of patients with Hedgehog signaling 
targeting agents [79]. Also a BMS-833923 maximum 
tolerable dose phase 1 clinical trial has been performed. 
Capecitabine and cisplatin were used in combination with 
BMS-833923 in drug naïve adenocarcinoma patients. The 
study was completed in 2013, but the findings have not 
yet been reported (NCT00909402). Thus a potential role 
for Hedgehog inhibition in gastric is far from evident and 
requires more clinical testing.
Clinical Applications
Gastric cancer has long been seen as one of the 
most difficult gastrointestinal malignancies to treat. 
Encouragingly, recent progress with targeted therapies 
offers hope for patients with advanced gastric cancer and 
is substantially expanding the therapeutic armamentarium 
with regard to this infaust disease. As these treatments 
continue to be developed, we must focus on determination 
of predictive markers, and preferably co-develop drugs 
with these markers. The mechanisms underlying primary 
or acquired resistance to targeted agents also should be 
clarified to help further drug development[12]. Developing 
anti-Shh monoclonal antibodies as Shh antagonists is an 
area to explore where Hedgehog signaling pathway can 
be blocked at different levels [80]. Gastric cancer is a 
multigenic disorder influenced by Helicobacter pylori 
infection and salt intake r. Single nucleotide polymorphism 
(SNP) and copy number polymorphism (CNP) of genes 
encoding Hedgehog signaling molecules would be utilized 
for genetic screening of gastric cancer. Also, cDNA-PCR, 
microarray, and ELISA detecting aberrant Hedgehog 
signaling activation would be used for optional therapeutic 
choice. Genetic testing and precise selection of therapeutic 
options would contribute to the realization of personalized 
medicine. Several limitations account for poor treatment 
outcomes in gastric cancer patients amongst which include 
tumor heterogeneity. Due to traditional classification of 
gastric cancer into two categories in casu undifferentiated 
and differentiated types, obvious biological differences 
must exist. Additionally, molecular subgroups exist gastric 
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cancer category; these include chromosomal instability 
tumors, stable genomically tumors, unstable microsatellite 
tumor and Epstein–Barr virus tumor-positive [81]. It is 
well possible that stratification for subtype is way forward 
with regard to Hedgehog inhibition for the treatment of 
gastric cancer.
CONCLUSION AND FUTURE DIRECTIONS
While there is good evidence that Smoothened 
inhibition may be useful for a selection of gastric cancers, 
we feel that its untargeted application on gastric cancer 
patients, in general, is likely to prove disappointing. In this 
sense efforts to select patients characterized by unusually 
high SMO expression in gastric tumor material with high 
probability to have cancers that are truly dependent on a 
functional Hedgehog pathway may likely yield positive 
results. As both approaches are currently being attempted 
in clinical trials, it should prove interesting to see whether 
this notion holds true.
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